The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

被引：0

作者：

Al-Sawaf, Othman ^{[1
,2
,3
]}

Fuerstenau, Moritz ^{[1
,2
,3
]}

Giza, Adam ^{[1
,2
,3
]}

Robrecht, Sandra ^{[1
,2
,3
]}

Von Tresckow, Julia ^{[4
]}

Fink, Anna Maria ^{[1
,2
,3
]}

Simon, Florian ^{[1
,2
,3
]}

Tausch, Eugen ^{[5
]}

Schneider, Christof ^{[6
]}

Sivcheva, Liliya ^{[7
]}

Schwarer, Anthony ^{[8
]}

Loscertales, Javier ^{[9
]}

Weinkove, Robert ^{[10
]}

Strumberg, Dirk ^{[11
]}

Kilfoyle, Allanah R. ^{[12
]}

Juliusson, Gunnar ^{[13
]}

Da Cunha-Bang, Caspar ^{[14
]}

Illmer, Thomas

Gregor, Michael ^{[15
]}

Thornton, Patrick ^{[16
]}

Janssens, Ann ^{[17
]}

Tadmor, Tamar ^{[18
]}

Lindstrom, Vesa ^{[19
,20
]}

Staber, Philipp Bernhard ^{[21
]}

Levin, Mark-David ^{[22
]}

Wendtner, Clemens-Martin ^{[23
]}

Kreuzer, Karl-Anton ^{[1
,2
,3
]}

Ritgen, Matthias ^{[24
]}

Stilgenbauer, Stephan ^{[25
]}

Kater, Arnon P. ^{[26
]}

Niemann, Carsten Utoft ^{[27
]}

Fischer, Kirsten ^{[1
,2
,3
]}

Eichhorst, Barbara F. ^{[28
]}

Hallek, Michael ^{[29
]}

机构：

[1] Univ Cologne, Fac Med, Cologne, Germany

[2] Univ Cologne, Univ Hosp Cologne, Dept Internal Med 1, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Cologne, Germany

[3] Univ Cologne, German CLL Study Grp, Cologne, Germany

[4] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Clin Hematol & Stem Cell Transplantat, Essen, Germany

[5] Ulm Univ, Div CLL, Dept Internal Med 3, Ulm, Germany

[6] Univ Ulm, Div CLL, Dept Internal Med 3, Ulm, Germany

[7] Multiprofile Hosp Act Treatment HristoBotev, Dept Internal Med 1, Vratsa, Bulgaria

[8] Box Hill Hosp, Melbourne, Vic, Australia

[9] Hosp Univ La Princesa, Madrid, Spain

[10] Wellington Rerenga Ora Blood & Canc Ctr, Capital & Coast Dist Hlth Board, Wellington, New Zealand

[11] Marien Hosp, Herne, Germany

[12] Palmerston North Hosp, Palmerston North, New Zealand

[13] Lund Univ Canc Ctr, Dept Hematol, Lund, Sweden

[14] Rigshosp, Copenhagen, Denmark

[15] Cantonal Hosp Lucerne, Div Hematol, Luzern, Switzerland

[16] Beaumont Hosp, Canc Trials Ireland, Dept Haematol, RCSI, Dublin, Ireland

[17] Univ Hosp Leuven, Leuven, Belgium

[18] Bnai Zion Med Ctr, Hematol, Haifa, Israel

[19] Helsinki Univ Hosp, Dept Hematol, Ctr Comprehens Canc, Helsinki, Finland

[20] Univ Helsinki, Helsinki, Finland

[21] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Med 1, Vienna, Austria

[22] Albert Schweitzer Hosp, Dept Internal Med, Dordrecht, Netherlands

[23] German CLL Study Grp, Munich Clin Schwabing, Dept Hematol Oncol Immunol Palliat Care Infect Di, Munich, Germany

[24] Univ Schleswig Holstein, Dept Internal Med 2, Kiel, Germany

[25] Univ Hosp Ulm, Div CLL, Dept Internal Med 3, Ulm, Germany

[26] Acad Med Ctr, Amsterdam, Netherlands

[27] Copenhagen Univ Hosp, Dept Hematol, Rigshosp, Copenhagen, Denmark

[28] Univ Cologne, Cologne, Germany

[29] Univ Hosp Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Cologne, Germany

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-188827

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：8

共 50 条

[31] Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study
Leblond, Veronique
Aktan, Melih
Ferra Coll, Christelle M.
Dartigeas, Caroline
Kisro, Jens
Montillo, Marco
Raposo, Joao
Merot, Jean-Louis
Robson, Susan
Gresko, Ekaterina
Bosch, Francesc
Stilgenbauer, Stephan
Foa, Robin
HAEMATOLOGICA, 2018, 103 (11) : 1889 - 1898
[32] SYSTEMATIC REVIEW OF THE RECENT EVIDENCE OF EFFICACY AND SAFETY OF CHLORAMBUCIL IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
Lepretre, S.
Dartigeas, C.
Feugier, P.
Marty, M.
Salles, G.
HAEMATOLOGICA, 2014, 99 : 590 - 590
[33] A phase II study investigating safety and efficacy of dose reduced fludarabine, cyclophosphamide and obinutuzumab versus chlorambucil and obinutuzumab in untreated, comorbid, elderly patients with chronic lymphocytic leukemia (CLL)
Mulligan, Stephen
Tam, Constantine
Badoux, Xavier
Kuss, Bryone
LEUKEMIA & LYMPHOMA, 2015, 56 : 25 - 26
[34] Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Freise, Kevin J.
Jones, Aksana K.
Eckert, Doerthe
Mensing, Sven
Wong, Shekman L.
Humerickhouse, Rod A.
Awni, Walid M.
Salem, Ahmed Hamed
CLINICAL PHARMACOKINETICS, 2017, 56 (05) : 515 - 523
[35] PHARMACOECONOMIC ANALISYS OF OBINUTUZUMAB PLUS CHLORAMBUCIL IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA AND COEXISTING CONDITIONS
Kolbin, A.
Vilum, I
Balykina, Y.
Proskurin, M.
VALUE IN HEALTH, 2017, 20 (09) : A438 - A438
[36] Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/ Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Stilgenbauer, Stephan
Morschhauser, Franck
Wendtner, Clemens-Martin
Cartron, Guillaume
Hallek, Michael
Eichhorst, Barbara F.
Kozloff, Mark
Giever, Thomas A.
Lozanski, Gerard
Punnoose, Elizabeth A.
Wang, Jue
Hilger, James
Mobasher, Mehrdad
Salles, Gilles
BLOOD, 2016, 128 (22)
[37] Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Kevin J. Freise
Aksana K. Jones
Doerthe Eckert
Sven Mensing
Shekman L. Wong
Rod A. Humerickhouse
Walid M. Awni
Ahmed Hamed Salem
Clinical Pharmacokinetics, 2017, 56 : 515 - 523
[38] Cost-Effectiveness Analysis of Obinutuzumab Versus Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Reyes, Carolina
Gazauskas, Gregory
Becker, Ursula
Moreno, Santiago
Veenstra, David L.
BLOOD, 2014, 124 (21)
[39] Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Previously Untreated Chronic Lymphocytic Leukemia
Shah, Arpita
ANNALS OF PHARMACOTHERAPY, 2014, 48 (10) : 1356 - 1361
[40] Majic: A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Davids, Matthew S.
Mato, Anthony R.
Hum, Juliette
Wargo, Susana
Emeribe, Ugochinyere
Shahkarami, Mina
Sokolowski, Kevin
Biondo, Juliana M. L.
Abhyankar, Sarang
Hermann, Rick
Sharman, Jeff P.
BLOOD, 2021, 138

← 1 2 3 4 5 →